Can Multiple Myeloma treatment cause heart problems years later

Heart Problems and Multiple Myeloma Treatment: What You Should Know

Yes, certain multiple myeloma treatments can affect heart function, both during treatment and potentially years later. This is an important consideration in your care plan, and it's something your oncology team monitors carefully.

Which Treatments Can Affect the Heart?

According to the NCCN Guidelines for Multiple Myeloma, several treatment types have known cardiac (heart) effects:

Chemotherapy drugs like doxorubicin (Adriamycin) are well-documented to potentially cause heart damage. This can happen during treatment or develop months to years afterward. The risk increases with higher cumulative doses over time.

Proteasome inhibitors (such as bortezomib/Velcade and carfilzomib/Kyprolis) can occasionally cause heart-related side effects, though serious cardiac problems are less common than with some chemotherapy drugs.

Immunomodulators (lenalidomide/Revlimid, pomalidomide/Pomalyst, thalidomide/Thalomid) may increase the risk of blood clots, which can strain the heart.

Monoclonal antibodies and bispecific antibodies can rarely cause heart function issues in some patients.

How Doctors Monitor for Heart Problems

The NCCN Guidelines recommend that patients receiving certain myeloma treatments may need an echocardiogram (an ultrasound of the heart). This test:

• Views the structure of your heart
• Checks how well it's pumping
• Can detect early signs of damage before you feel symptoms

This monitoring is particularly important because heart damage can develop silently—you might not notice symptoms until significant damage has occurred.

Long-Term Heart Effects

Heart problems from myeloma treatment can develop:

• During treatment (acute effects)
• Months after treatment ends (subacute effects)
• Years later (late effects)

The timing and severity depend on:

• Which specific drugs you received
• The doses and duration of treatment
• Your age and overall heart health before treatment
• Whether you have other risk factors (high blood pressure, diabetes, smoking history)

What This Means for Your Care

Questions to ask your oncology team:

1. Which of my specific treatment drugs have cardiac risks? (Get the names and doses)

2. Do I need baseline heart testing before starting treatment? (This gives doctors a comparison point)

3. How often will my heart be monitored during and after treatment? (Echocardiograms, EKGs, or blood tests for heart markers)

4. What symptoms should I watch for? (Shortness of breath, chest pain, unusual fatigue, swelling in legs/feet, irregular heartbeat)

5. Are there ways to protect my heart during treatment? (Some medications can reduce cardiac risk)

6. How long should I have heart monitoring after treatment ends? (This varies based on your specific treatment)

7. Should I modify exercise, diet, or other lifestyle factors? (Heart-healthy habits may help)

The Bottom Line

While heart problems are a real potential side effect of some myeloma treatments, modern oncology teams are very aware of this risk. According to the NCCN Guidelines, cardiac monitoring is built into standard care for patients receiving treatments known to affect the heart. Early detection through regular monitoring means problems can often be caught and managed before they become serious.

The benefits of treating your myeloma typically outweigh the cardiac risks, especially with modern monitoring and supportive care strategies. However, this is absolutely something to discuss openly with your care team so you understand your individual risk profile and what to watch for.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.